{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-058706","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2026-05-11T20:43:06+00:00","discovered_at":"2026-05-11T20:44:00.476566+00:00","generated_at":"2026-05-11T20:46:53.036790+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ArriVent BioPharma expands at-the-market equity program by up to $250M","bullets":["Filed prospectus supplement on May 11, 2026 to sell up to $250,000,000 of common stock via ATM.","Jefferies LLC named as sales agent under existing Open Market Sale Agreement dated Feb 3, 2025.","Proceeds will be used for general corporate purposes; no specific use disclosed.","Offering is made under automatic shelf registration statement (Form S-3ASR, File 333-284661)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058706","json":"https://secwatch.observer/filing/0001104659-26-058706.json","markdown":"https://secwatch.observer/filing/0001104659-26-058706.md","text":"https://secwatch.observer/filing/0001104659-26-058706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926058706/0001104659-26-058706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926058706/tm2614177d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T20:46:53.036790+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}